Literature DB >> 9591814

Effect of onychomycosis on quality of life.

L A Drake1, R K Scher, E B Smith, G A Faich, S L Smith, J J Hong, M J Stiller.   

Abstract

BACKGROUND: Onychomycosis impairs normal nail functions, causes considerable pain, interferes with daily activities, and has negative psychosocial effects.
OBJECTIVE: Our purpose was to determine patients' perception of onychomycosis on the quality of life.
METHODS: A total of 258 patients with confirmed onychomycosis were surveyed by telephone at three centers. Responses to a standardized quality-of-life questionnaire were analyzed for patient demographics, physical and functional impact, psychosocial impact, and economic impact.
RESULTS: Highest positive responses were nail-trimming problems (76%), embarrassment (74%), pain (48%), nail pressure (40%), and discomfort wearing shoes (38%). Ability to pick up small objects was impaired in 41% of subjects with fingernail involvement. More than 58 onychomycosis-related sick days and 468 medical visits (1.8 per subject) were reported during a 6-month period.
CONCLUSION: Onychomycosis has significant social, psychologic, health, and occupational effects. Relevance of quality-of-life issues to overall health, earning potential, and social functioning should prompt reconsideration of the value of aggressive treatment of and financial coverage for onychomycosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9591814     DOI: 10.1016/s0190-9622(98)70199-9

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  30 in total

Review 1.  Onychomycosis in the elderly.

Authors:  A K Gupta
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

Review 2.  Oral antifungal medication for toenail onychomycosis.

Authors:  Sanne Kreijkamp-Kaspers; Kate Hawke; Linda Guo; George Kerin; Sally Em Bell-Syer; Parker Magin; Sophie V Bell-Syer; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2017-07-14

Review 3.  A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.

Authors:  A K Gupta; N H Shear
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

4.  In vitro antifungal activity of ME1111, a new topical agent for onychomycosis, against clinical isolates of dermatophytes.

Authors:  M Ghannoum; N Isham; L Long
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

5.  Early Visible Improvements during K101-03 Treatment: An Open-Label Multicenter Clinical Investigation in Patients with Onychomycosis and/or Nail Psoriasis.

Authors:  Bianca Maria Piraccini; Michela Starace; Anders Toft
Journal:  Dermatology       Date:  2017-08-05       Impact factor: 5.366

Review 6.  Patient-Reported Outcomes in Onychomycosis: A Review of Psychometrically Evaluated Instruments in Assessing Treatment Effectiveness.

Authors:  Jenny Wang; Lauren E Wiznia; Evan A Rieder
Journal:  Skin Appendage Disord       Date:  2017-04-21

7.  Toenail onychomycosis in a Portuguese geriatric population.

Authors:  N Dias; C Santos; M Portela; N Lima
Journal:  Mycopathologia       Date:  2011-03-02       Impact factor: 2.574

8.  Penetration of ((14)C)-Efinaconazole Topical Solution, 10%, Does Not Appear to be Influenced by Nail Polish.

Authors:  Joshua A Zeichner; Linda Stein Gold; Andrew Korotzer
Journal:  J Clin Aesthet Dermatol       Date:  2014-09

9.  Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life.

Authors:  Antonella Tosti; Bom E Elewski
Journal:  J Clin Aesthet Dermatol       Date:  2014-11

10.  Nail swelling as a pre-formulation screen for the selection and optimisation of ungual penetration enhancers.

Authors:  R H Khengar; S A Jones; R B Turner; B Forbes; M B Brown
Journal:  Pharm Res       Date:  2007-07-31       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.